Skip to Content

Rule

New Animal Drugs for Use in Animal Feeds; Diclazuril, Bacitracin Methylene Disalicylate, Bambermycins, and Virginiamycin

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of three new animal drug applications (NADA's) filed by Schering-Plough Animal Health Corp. The NADA's provide for use of the approved, single-ingredient diclazuril Type A medicated article together with approved, single-ingredient Type A medicated articles for either bacitracin methylene disalicylate (BMD), virginiamycin, or bambermycins to make two-way combination Type C medicated feeds used for prevention of coccidiosis, increased rate of weight gain, and improved feed efficiency in broiler chickens.

DATES:

This rule is effective August 17, 2000.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Charles J. Andres, Center for Veterinary Medicine (HFV-128), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-1600. Start Printed Page 50134

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Schering-Plough Animal Health Corp., 1095 Morris Ave., P.O. Box 3182, Union, NJ 07083, filed three NADA's that provide for use of ClinacoxTM (0.91 grams per pound (g/lb) diclazuril activity) Type A medicated article together with other approved, single-ingredient Type A medicated articles to make two-way combination Type C medicated broiler chicken feeds used for the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mitis (mivati), and E. maxima. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima. The combination Type C medicated feeds are also used for increased rate of weight gain and for improved feed efficiency.

NADA 141-153 provides for use of ClinacoxTM and BMD® (10, 25, 30, 50, 60, or 75 g/lb bacitracin activity as BMD) Type A medicated articles to make combination Type C medicated broiler chicken feed containing 0.91 g/ton diclazuril and 4 to 50 g/ton BMD® and is approved as of January 13, 2000.

NADA 141-158 provides for use of ClinacoxTM and Flavomycin ® (2, 4, or 10 g/lb of bambermycins activity) Type A medicated articles to make combination Type C medicated broiler chicken feed containing 0.91 g/ton diclazuril and 1 to 2 g/ton bambermycins and is approved as of July 3, 2000.

NADA 141-090 provides for use of ClinacoxTM and Stafac® (5, 10, 20, 50, or 227 g/lb virginiamycin activity) Type A medicated articles to make combination Type C medicated broiler chicken feed containing 0.91 g/ton diclazuril and 5 or 5 to 15 g/ton virginiamycin and is approved as of January 13, 2000. The combination Type C medicated feed containing 5 g/ton virginiamycin is used for prevention of coccidiosis, increased rate of weight gain, and improved feed efficiency. The combination Type C medicated feed containing 5 to 15 g/ton virginiamycin is used for prevention of coccidiosis and increased rate of weight gain only.

The regulations are amended in 21 CFR 558.76, §§ 558.95, 558.198 and 558.635 (21 CFR 558.95, 558.198 and 558.635) to reflect these approvals. The basis of approval for each application is discussed in separate freedom of information summaries.

Sections 558.95 and 558.635 are also amended editorially to consolidate the cross-references for approved combinations in paragraph (d) and to list them in alphabetical order.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of each application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(2) that these actions are of a type that do not individually or cumulatively have a significant effect on the human environment. Therefore, neither environmental assessments nor environmental impact statements are required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects in 21 CFR Part 558

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority Start Amendment Part

2. Section 558.76 is amended by redesignating paragraphs (d)(3)(v) through (d)(3)(xvii) as (d)(3)(vi) through (d)(3)(xviii) and by adding new paragraph (d)(3)(v) to read as follows:

End Amendment Part
Bacitracin methylene disalicylate.
* * * * *

(d) * * *

(3) * * *

(v) Diclazuril as in § 558.198.

* * * * *
Start Amendment Part

3. Section 558.95 is amended by revising paragraphs (d)(5)(i) through (d)(5)(iv) to read as follows:

End Amendment Part
Bambermycins.
* * * * *

(d) * * *

(5) Bambermycins may be used in combination with:

(i) Diclazuril as in § 558.198.

(ii) Halofuginone as in § 558.265.

(iii) Narasin alone or with roxarsone as in § 558.363.

(iv) Nicarbazine as in § 558.366.

Start Amendment Part

4. Section 558.198 is amended by revising paragraph (d) to read as follows:

End Amendment Part
Diclazuril.
* * * * *

(d) Conditions of use. (1) It is used in Type C feed as follows:

Diclazuril grams/tonCombination grams/tonIndications for useLimitationsSponsor
(i) 0.91 (1 part per million (ppm))Broiler chickens: For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis (mivati), and E. maxima. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima.Feed continuously. Not for use in hens producing eggs for human food.000061
(ii) 0.91 (1 ppm)Bacitracin methylene disalicylate 4 to 50Broiler chickens: As in item (i) of this table; for increased rate of weight gain and improved feed efficiency.As in item (i) of this table. Bacitracin methylene disalicylate provided by 046573.000061
Start Printed Page 50135
(iii) 0.91 (1 ppm)Bambermycins 1 to 2Broiler chickens: As in item (i) of this table); for increased rate of weight gain and improved feed efficiency.As in item (i) of this table. Bambermycins provided by 012799.000061
(iv) 0.91 (1 ppm)Virginiamycin 5Broiler chickens: As in item (i) of this table; for increased rate of weight gain and improved feed efficiency.As in item (i) of this table; Virginiamycin provided by 000069.000061
(v) 0.91 (1 ppm)Virginiamycin 5 to 15Broiler chickens: As in item (i) of this table; for increased rate of weight gain.As in item (i) of this table. Virginiamycin provided by 000069.000061

(2) [Reserved]

Start Amendment Part

5. Section 558.635 is amended by revising paragraphs (d)(4)(i) through (d)(4)(vii) to read as follows:

End Amendment Part
Virginiamycin.
* * * * *

(d) * * *

(4) Virginiamycin may be used in combination with:

(i) Amprolium and ethopabate as in § 558.58.

(ii) Diclazuril as in § 558.198.

(iii) Halofuginone as in § 558.265.

(iv) Lasalocid as in § 558.311.

(v) Monensin alone or with roxarsone as in § 558.355.

(vi) Salinomycin alone or with roxarsone as in § 558.550.

(vii) Semduramicin as in § 558.555.

Start Signature

Dated: July 26, 2000.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 00-20936 Filed 8-16-00; 8:45 am]

BILLING CODE 4160-01-F